Patent Granted to Autonomix Medical for Sensing Data Collection

 Autonomix Medical Inc. has received a U.S. patent that protects its proprietary technology used to collect and process sensing data for real-time physiological monitoring with broad applications in heart mapping, arterial mapping, parenchymal monitoring, central nervous system monitoring and implant, and robotic and wearable precision applications.

The U.S. Patent and Trademark Office issued Autonomix Medical U.S. patent 12,217,863 (‘863 patent) titled, “Medical Devices with Circuitry for Capturing and Processing Physiological Signals.”

“We are pleased to strengthen our patent protection for this potential groundbreaking technology. The continued positive data on its application, efficacy, and safety reinforce our confidence in its potential. We remain committed to advancing this innovation to address critical areas of unmet medical need. To date, our early clinical results have been highly encouraging for reducing pancreatic cancer pain. Beyond cancer pain, our technology holds promise for a broad range of conditions where nerve activity plays a key role, including hypertension within the cardiovascular space,” Autonomix Medical CEO Brad Hauser said.

Autonomix’s first-in-class technology platform uses a catheter-based microchip sensing array antenna that may detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary RF ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.

The company expects to submit an investigational device exemption (IDE) application and begin U.S. clinical trials this year to support a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the United States as a treatment for pancreatic cancer pain.

Autonomix is a medical device company advancing technologies to revolutionize the ways in which diseases involving the nervous system are diagnosed and treated. Its catheter-based microchip sensing array might enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. The firm is initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Autonomix Medical’s technology can address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. The technology is investigational and has not yet been cleared for marketing in the United States.